Results 11 to 20 of about 3,500 (185)

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes [PDF]

RMD Open
Objectives Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major adverse ...
Zoltan Szekanecz, Yoshiya Tanaka, Laurent Peyrin-Biroulet, Stefan Schreiber, René Westhovens, Xavier Mariette, Chris Watson, C Janneke van der Woude, Hugo ten Cate, Andreas Stallmach, Christina Charles-Schoeman, Sandrine Aspeslagh, Marc Schmalzing, Margaux Faes, Sven Borchmann, Christine Rudolph, Edmund V Ekoka Omoruyi, Paul Van Hoek, Ernest HS Choy, Tomasz Masior   +19 more
doaj   +2 more sources

Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres [PDF]

Drugs in Context
Background: Filgotinib, an oral Janus kinase 1 preferential inhibitor, has been shown to be an effective treatment for ulcerative colitis (UC) in pre-registration studies.
David Young, Sohail Rahmany, Deborah Taylor, Emma Davis, Michael Colwill, Sonia Kalyanji Mehta, Roisin Campbell, Karl Hazel, Karishma Sethi-Arora, Susan Ritchie, Ashley I Heinson, Helen Moyses, Keith Bodger, Emma Johnston, Lucy Hicks, Anjan Dhar, Jimmy Limdi, Rachel Cooney, John Paul Seenan, Kamal Patel, Alissa Walsh, Fraser Cummings   +21 more
doaj   +2 more sources

State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review [PDF]

Pharmaceuticals
Background/Objectives: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing inflammation and incomplete response to conventional therapies.
Yunseok Choi, Suhyun Lee, Hyeon Ji Kim, Taemin Park, Won Gun Kwack, Seungwon Yang, Eun Kyoung Chung   +6 more
doaj   +2 more sources

JAK Inhibitor and Crohn’s Disease [PDF]

Biomedicines
Crohn’s disease is a chronic inflammatory granulomatous disease of the gastrointestinal tract. The global incidence and prevalence of Crohn’s disease have significantly increased, largely due to genetic susceptibility, environmental changes, and ...
Mengyan Xu, Shi Wang, Sanping Xu, Rui Gong   +3 more
doaj   +2 more sources

Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment [PDF]

Frontiers in Medicine
IntroductionAchieving the primary treat-to-target (T2T) goal in rheumatoid arthritis (RA) remains challenging for many patients, reflecting limitations in the effectiveness of existing treatments. Our study examines factors influencing Janus kinase (JAK)
Cristina Martinez-Molina, Cristina Martinez-Molina, Silvia Vidal, Silvia Vidal, Cesar Diaz-Torne, Cesar Diaz-Torne, Cesar Diaz-Torne, Hye S. Park, Hye S. Park, Hye S. Park, Hèctor Corominas, Hèctor Corominas, Hèctor Corominas   +12 more
doaj   +3 more sources

Modern Strategies in the Pharmacotherapy of Inflammatory Bowel Diseases – A Literature Review [PDF]

Journal of Education, Health and Sport
Introduction and Aim: Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are chronic, immune-mediated disorders of the gastrointestinal tract.
Bartłomiej Czarnecki , Wiktor Werenkowicz, Aleksandra Boral, Dominika Kryś, Joanna Brzoza, Julia Koczur, Michał Górski, Wiktoria Pniok, Wojciech Kurkiewicz   +8 more
doaj   +3 more sources

Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data. [PDF]

Cancers (Basel)
The advent of Janus kinase (JAK) inhibitors, including tofacitinib, filgotinib, and upadacitinib, has significantly widened the therapeutic options for patients with inflammatory bowel disease (IBD).
Puca P, Del Gaudio A, Iaccarino J, Blasi V, Coppola G, Laterza L, Lopetuso LR, Colantuono S, Gasbarrini A, Scaldaferri F, Papa A.   +10 more
europepmc   +3 more sources

Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry. [PDF]

United European Gastroenterol J
ABSTRACT Background Filgotinib is a preferential Janus kinase 1 (JAK‐1) inhibitor registered for the treatment of ulcerative colitis (UC). Real‐world effectiveness of filgotinib, especially for difficult‐to‐treat (DTT, failure of ≥ 2 prior advanced therapies) patients, has been scarcely reported.
Naber MR, van der Meulen AE, Voorneveld PW, Veltkamp SHC, van Bodegraven AA, Bodelier A, Mujagic Z, Pierik M, Verleye LMM, Duijvestein M, Bouwknegt DG, Visschedijk MC, Srivastava N, West RL, Oldenburg B, Löwenberg M, van Schaik FDM, Dutch ICC Registry.   +17 more
europepmc   +2 more sources

Filgotinib to Treat Acute Severe Refractory Ulcerative Colitis: A Case Report and Review of the Literature [PDF]

Case Reports in Gastroenterology
Introduction: Acute severe ulcerative colitis (ASUC) is a serious complication affecting 9%–15% of patients with UC within 3 months of diagnosis and up to 28% of patients during the course of the disease.
Giuliana Vespere, Silvia Sedda, Pasquale Madonna, Roberta Abete, Alfredo D'Avino, Manuela Maione, Marina Lugarà, Antonietta Tazza, Franco Scaldaferri, Giuseppe Vitiello, Leonardo De Luca   +10 more
doaj   +2 more sources

Tofacitinib-Induced Weight Gain in Context: comment on the article by Wollenhaupt et al. [PDF]

ACR Open Rheumatol
ACR Open Rheumatology, Volume 8, Issue 2, February 2026.
Palmowski A, Buttgereit F, Simon D, Kleyer A, Drzeniek NM.   +4 more
europepmc   +2 more sources